Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Acumen files periodic reports and current reports with the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q and 8‑K, in connection with its development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease.
Through its 8‑K filings, Acumen reports material events such as quarterly financial results, business highlights, strategic collaboration agreements and changes in its Board of Directors. For example, recent 8‑Ks have covered the company’s financial condition, the posting of updated corporate presentations, and the appointment of a new chairman of the board. These filings complement press releases that discuss the progress of the Phase 2 ALTITUDE-AD trial, the Enhanced Brain Delivery (EBD™) collaboration with JCR Pharmaceuticals, and other corporate developments.
On this page, users can also track how Acumen describes its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ABOS, and its use of collaborations and option agreements to support development of AβO-targeted therapies. While detailed insider trading information would appear in Form 4 filings and executive compensation in proxy materials, this hub focuses on the full range of EDGAR-reported documents.
Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight important sections in lengthy reports such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q, and help readers quickly understand how new disclosures relate to Acumen’s Alzheimer’s disease programs and financial position.
Acumen Pharmaceuticals Chief Medical Officer Eric Siemers reported new equity awards from the company. On January 16, 2026, he received 99,133 shares of Common Stock at a price of $0, described as a restricted stock unit award that vests in three equal annual installments starting one year after the grant date, subject to continued service. The filing also shows a grant of an employee stock option for 148,700 shares of Common Stock at an exercise price of $1.89 per share, vesting in 48 equal monthly installments and expiring on January 16, 2036. Following these grants, Siemers directly owns 258,597 shares of Common Stock and 148,700 stock options.
Acumen Pharmaceuticals Chief Operating Officer Barton Russell reported new equity awards in the company. On 01/16/2026, he received 84,600 shares of Common Stock in the form of restricted stock units, granted at a price of $0. These RSUs vest in three equal annual installments starting one year after the grant date, as long as he continues in service.
On the same date, he was also granted an employee stock option for 126,900 shares of Common Stock with an exercise price of $1.89 per share. The option vests in 48 equal monthly installments and is fully vested on the fourth anniversary of the grant date, subject to continued service. After these transactions, Russell directly beneficially owned 207,869 shares of Common Stock and 126,900 stock options.
Acumen Pharmaceuticals Chief Regulatory Officer Amy Schacterle reported new equity awards. On January 16, 2026, she received 84,600 shares of Common Stock as a restricted stock unit award at a reported price of
She was also granted an employee stock option for 126,900 shares of Common Stock with an exercise price of
Acumen Pharmaceuticals reported that its President and Chief Development Officer, James J. Doherty, received new equity awards. On January 16, 2026, he was granted 166,867 restricted stock units (RSUs)220,900. Each RSU represents the right to receive one share of common stock and will vest in three equal annual installments starting one year after the grant date, as long as he remains in continuous service.
On the same date, Doherty also received an employee stock option covering 250,300 shares of common stock with an exercise price of $1.89 per share. These options were granted at no upfront cost and will vest in 48 equal monthly installments so that the option is fully vested on the fourth anniversary of the grant date, subject to his continued service with the company.
Acumen Pharmaceuticals insider Derek Meisner has filed a notice to sell shares. The Form 144 shows a planned sale of 2,247 shares of Acumen Pharmaceuticals common stock through Merrill Lynch, with an aggregate market value of
The filing notes that 60,573,425 shares of common stock were outstanding. It also lists prior sales by Meisner over the past three months, including separate sales of 4,000, 10,898, 11,770, 36,911, 5,200, and 8,548 shares of common stock on various dates in early
Acumen Pharmaceuticals, Inc. stockholder Eric Siemers has filed a notice to sell 2,331 shares of common stock on or about 01/21/2026 through Merrill Lynch on NASDAQ, with an aggregate market value of $4,203.85. These shares were acquired on 01/17/2026 upon vesting of a restricted stock unit award granted under the issuer’s equity compensation plan, with payment described as equity compensation rather than cash.
Acumen Pharmaceuticals had 60,573,425 shares of common stock outstanding for this class at the time referenced. Over the prior three months, the same seller reported additional sales of 4,000 and 6,834 common shares, generating gross proceeds of $7,834.80 and $13,442.82, respectively. By signing, the seller represents that he is not aware of any undisclosed material adverse information about the company’s operations.
Acumen Pharmaceuticals insider plans additional stock sale under Rule 144. A holder of Acumen Pharmaceuticals, Inc. (ABOS) common stock has filed a notice to sell 2,315 shares through Merrill Lynch on or about 01/21/2026 on the NASDAQ, with an indicated aggregate market value of $4,180.88. The filing notes that 60,573,425 shares of common stock were outstanding.
The 2,315 shares to be sold were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan. The same individual, Russell Barton, has already sold several blocks of Acumen common stock during January 2026, including 4,000 shares on 01/05/2026 for gross proceeds of $7,832.50 and 3,618 shares on 01/06/2026 for gross proceeds of $7,114.46.
Acumen Pharmaceuticals, Inc. insider Matt Zuga filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 2,473 shares of common stock through Merrill Lynch on or about January 21, 2026 on NASDAQ, with an indicated aggregate market value of $4,469.18. The shares came from the vesting of a restricted stock unit award on January 17, 2026 granted as part of the issuer’s equity compensation plan.
The notice also lists recent sales of Acumen common stock by Zuga over the past three months. These include separate sales of 4,000, 5,100, 5,805, and 6,888 shares on January 5–8, 2026, with gross proceeds of $7,842.33, $10,027.50, $11,565.85, and $12,513.07, respectively. By signing, the seller represents that he is not aware of undisclosed material adverse information about the company.
Acumen Pharmaceuticals insider files to sell additional shares under Rule 144. A holder plans to sell 9,346 shares of Acumen Pharmaceuticals common stock through Merrill Lynch on or about 01/21/2026, with an aggregate market value of
The shares to be sold were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan. The notice also lists prior sales over the past three months by Daniel O’Connell, including multiple common stock transactions in early January 2026 with individual sale amounts ranging from 4,649 to 37,755 shares and corresponding gross proceeds disclosed for each date.
Acumen Pharmaceuticals CFO & Chief Business Officer Matt Zuga reported a small insider sale of company common stock. On January 8, 2026, he sold 6,888 shares at a weighted average price of $1.8166 per share, with individual trades executed between $1.72 and $1.95.
According to the disclosure, these shares were sold through an automatic “sell to cover” transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units. The transaction was made under a Rule 10b5-1 trading plan adopted on June 30, 2025. After this activity, Zuga beneficially owned 209,951 shares of Acumen Pharmaceuticals common stock.